RxDoctor Payments Data

Hani Ahmad, MD

Psychiatry · Fort Wayne, INNPI 1790711604

Payments from drug & device makers

$4,598in general payments, 2019–2025

Across 259 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$970
  • Otsuka America Pharmaceutical, Inc.$542
  • Alkermes, Inc.$503
  • Lundbeck LLC$493
  • Teva Pharmaceuticals USA, Inc.$296
  • Supernus Pharmaceuticals, Inc.$203
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,46997%
  • Education$1293%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,598 in reported general payments places this provider in the 85th percentile of 514 psychiatry providers in Indiana.

See all psychiatry providers in Indiana

Medicare billing

Part B allowed, 2024
$4,753
Medicare patients
32
Services billed
60

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole113$314,468
Invega SustennaPaliperidone Palmitate72$242,416
RexultiBrexpiprazole96$168,061
IngrezzaValbenazine Tosylate18$152,447
TrintellixVortioxetine Hydrobromide100$65,076
Aripiprazole456$61,642
VraylarCariprazine Hcl42$61,291
CaplytaLumateperone Tosylate34$58,371
BelsomraSuvorexant76$33,730
Paliperidone ErPaliperidone80$29,799
Risperdal ConstaRisperidone Microspheres11$26,608
AuvelityDextromethorphan Hbr/Bupropion21$19,605
Quetiapine Fumarate ErQuetiapine Fumarate90$14,846
Lurasidone Hcl55$13,127
Olanzapine267$12,604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$542$482,529209 claims
Johnson & JohnsonInvega Sustenna, Risperdal Consta$48$269,02483 claims
Neurocrine Biosciences, Inc.Ingrezza$171$152,44718 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$54$76,479130 claims
AbbVieVraylar$82$61,29142 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$98$58,37134 claims
Axsome Therapeutics, Inc.Auvelity$131$19,60521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 514 psychiatry providers in Indiana.

Other psychiatry in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →